Mariëtte Schrier

4.2k citations

13 papers · 3.4k indexed · 3 hit papers · h-index 9

Co-authors: Reuven Agami Carlos le Sage Remco Nagel David A. Egan Martijn Kedde Anja Duursma Jarno Drost Alexander Griekspoor
Topics: RNA modifications and cancer (7 papers)MicroRNA in disease regulation (6 papers)Cancer-related molecular mechanisms research (4 papers)
Cited by: Cancer Research Molecular Biology Reproductive Medicine
Journals: Cell Journal of Clinical Oncology The EMBO Journal
Partner nations: Netherlands Italy United States

In The Last Decade

Mariëtte Schrier

13 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Genetic Screen Implicates miRNA-372 and miRNA-373 As Oncogenes in Testicular Germ Cell Tumors

2006 1.0k citations P. Mathijs Voorhoeve, Carlos le Sage et al. Cell profile →
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis

2008 800 citations Qihong Huang, Kiranmai Gumireddy et al. Nature Cell Biology profile →
Regulation of the p27Kip1 tumor suppressor by miR‐221 and miR‐222 promotes cancer cell proliferation

2007 651 citations Carlos le Sage, Remco Nagel et al. The EMBO Journal profile →

Peers

Countries citing papers authored by Mariëtte Schrier

Since Specialization

Citations

This map shows the geographic impact of Mariëtte Schrier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mariëtte Schrier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mariëtte Schrier more than expected).

Fields of papers citing papers by Mariëtte Schrier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mariëtte Schrier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mariëtte Schrier. The network helps show where Mariëtte Schrier may publish in the future.

Co-authorship network of co-authors of Mariëtte Schrier

This figure shows the co-authorship network connecting the top 25 collaborators of Mariëtte Schrier. A scholar is included among the top collaborators of Mariëtte Schrier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mariëtte Schrier. Mariëtte Schrier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	LBA18 POSEIDON randomized phase II trial: Tamoxifen (TAM) + taselisib or placebo (PLA) in patients (pts) with hormone receptor positive (HR+)/HER2- metastatic breast cancer (MBC) 2021 ·Annals of Oncology ·Mafalda Oliveira,Richard D. Baird,(unknown),(unknown),(unknown),(unknown),Susana Muñoz,(unknown),C. Saura Manich,Mariëtte Schrier,Ingrid A.M. Mandjes,Karolina Sikorska,Margaret Schot,(unknown),(unknown),Karin Beelen,Javier Cortés,Carlos Caldas,Sabine C. Linn	3
2	A Phase Ii, Single-Arm Trial Of Neoadjuvant Axitinib Plus Avelumab In Patients With Localized Renal Cell Carcinoma Who Are At High Risk Of Relapse After Nephrectomy (Neoavax) 2019 ·Future Oncology ·Axel Bex,(unknown),Mariëtte Schrier,Niels M. Graafland,Teele Kuusk,Kees Hendricksen,Brunolf W. Lagerveld,Patricia Zondervan,(unknown),Christian U. Blank,Sofie Wilgenhof,John B.A.G. Haanen	25
3	A phase 2, single-arm trial of neoadjuvant axitinb plus avelumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx). 2018 ·Journal of Clinical Oncology ·Axel Bex,Johannes V. van Thienen,Mariëtte Schrier,Kees Hendricksen,Christian U. Blank,John B.A.G. Haanen	2
4	POSEIDON trial phase 1b results: Safety and preliminary efficacy of the isoform selective PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC) patients (pts) - including response monitoring by plasma circulating tumor (ct) DNA. 2016 ·Journal of Clinical Oncology ·Richard D. Baird,Annelot van Rossum,Mafalda Oliveira,Karin Beelen,Javier García-Corbacho,Ingrid A.M. Mandjes,Anne-Laure Vallier,Erik van Werkhoven,Sanjeev Kumar,Harm van Tinteren,Emma Beddowes,Hilde Rosing,Mariëtte Schrier,(unknown),Cristina Saura,René Bernards,Josep Tabernero,Javier Cortés,Carlos Caldas,Sabine C. Linn	7
5	E2F mediates enhanced alternative polyadenylation in proliferation 2012 ·Genome biology ·Ran Elkon,Jarno Drost,Gijs van Haaften,Mathias Jenal,Mariëtte Schrier,(unknown),Reuven Agami	122
6	The micrornas mir-373 and mir-520c promote tumor migration, invasion and metastasis 2008 ·Cancer Research ·Qihong Huang,Kiranmai Gumireddy,Mariëtte Schrier,Carlos le Sage,Remco Nagel,Suresh Nair,David Egan,An‐Ping Li,Guanghua Huang,Andres J. Klein–Szanto,(unknown),Dionyssios Katsaros,George Coukos,Lin Zhang,Ellen Puré,Reuven Agami	1
7	miR-148 targets human DNMT3b protein coding region 2008 ·RNA ·Anja Duursma,Martijn Kedde,Mariëtte Schrier,Carlos le Sage,Reuven Agami	448
8	The microRNAs miR-373 and miR-520c promote tumour invasion and metastasisbreakdown → 2008 ·Nature Cell Biology ·Qihong Huang,Kiranmai Gumireddy,Mariëtte Schrier,Carlos le Sage,Remco Nagel,Suresh Nair,David A. Egan,An‐Ping Li,Guanghua Huang,Andres J. Klein–Szanto,Phyllis A. Gimotty,Dionyssios Katsaros,George Coukos,Lin Zhang,Ellen Puré,Reuven Agami	800
9	Regulation of the p27Kip1 tumor suppressor by miR‐221 and miR‐222 promotes cancer cell proliferationbreakdown → 2007 ·The EMBO Journal ·Carlos le Sage,Remco Nagel,David A. Egan,Mariëtte Schrier,Elly Mesman,Annunziato Mangiola,(unknown),Giulio Maira,Neri Mercatelli,Silvia Anna Ciafrè,Maria Giulia Farace,Reuven Agami	651
10	A Genetic Screen Implicates miRNA-372 and miRNA-373 as Oncogenes in Testicular Germ Cell Tumors 2007 ·Advances in experimental medicine and biology ·P. Mathijs Voorhoeve,Carlos le Sage,Mariëtte Schrier,Ad Gillis,Hans Stoop,Remco Nagel,Ying Poi Liu,(unknown),Jarno Drost,Alexander Griekspoor,Eitan Zlotorynski,Norikazu Yabuta,Gabriella De Vita,Hiroshi Nojima,Leendert H. J. Looijenga,Reuven Agami	126
11	A Genetic Screen Implicates miRNA-372 and miRNA-373 As Oncogenes in Testicular Germ Cell Tumorsbreakdown → 2006 ·Cell ·P. Mathijs Voorhoeve,Carlos le Sage,Mariëtte Schrier,Ad Gillis,Hans Stoop,Remco Nagel,Ying Poi Liu,(unknown),Jarno Drost,Alexander Griekspoor,Eitan Zlotorynski,Norikazu Yabuta,Gabriella De Vita,Hiroshi Nojima,Leendert H. J. Looijenga,Reuven Agami	1023
12	Transport kinetics of FMRP containing the I304N mutation of severe fragile X syndrome in neurites of living rat PC12 cells 2004 ·Experimental Neurology ·Mariëtte Schrier,(unknown),Surya A. Reis,M. Rifé,(unknown),(unknown),Ben A. Oostra,Rob Willemsen	25
13	Transport of Fragile X Mental Retardation Protein via Granules in Neurites of PC12 Cells 2002 ·Molecular and Cellular Biology ·Yolanda de Diego‐Otero,Lies‐Anne Severijnen,Gert van Cappellen,Mariëtte Schrier,Ben A. Oostra,Rob Willemsen	124

About Mariëtte Schrier

Mariëtte Schrier is a scholar working on Cancer Research, Molecular Biology and Oncology, having authored 13 papers that have together received 3.4k indexed citations. Recurring topics across this work include RNA modifications and cancer (7 papers), MicroRNA in disease regulation (6 papers) and Cancer-related molecular mechanisms research (4 papers). The work is most often cited by research in Cancer Research (2.4k citations), Molecular Biology (2.8k citations) and Reproductive Medicine (110 citations). Mariëtte Schrier has collaborated with scholars based in Netherlands, Italy and United States. Frequent co-authors include Reuven Agami, Carlos le Sage, Remco Nagel, David A. Egan, Martijn Kedde, Anja Duursma, Jarno Drost, Alexander Griekspoor, Hiroshi Nojima and P. Mathijs Voorhoeve. Their work appears in journals such as Cell, Journal of Clinical Oncology and The EMBO Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact